These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 218118)

  • 1. Prostacyclin (PGI2) decreases the cyclic AMP level in coronary arteries.
    Schrör K; Rösen P
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Jan; 306(1):101-3. PubMed ID: 218118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostacyclin increases cAMP in coronary arteries.
    Kukovetz WR; Holzmann S; Wurm A; Pöch G
    J Cyclic Nucleotide Res; 1979 Dec; 5(6):469-76. PubMed ID: 231612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of coronary arterial relaxation by prostacyclin.
    Holzmann S; Kukovetz WR; Schmidt K
    J Cyclic Nucleotide Res; 1980; 6(6):451-60. PubMed ID: 6163806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostacyclin stimulation of dog arterial cyclic AMP levels.
    Miller OV; Aiken JW; Hemker DP; Shebuski RJ; Gorman RR
    Prostaglandins; 1979 Dec; 18(6):915-25. PubMed ID: 232764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of cyclic AMP by prostacyclin is accompanied by relaxation of bovine coronary arteries and contraction of rabbit aortic rings.
    Vegesna RV; Diamond J
    Eur J Pharmacol; 1986 Aug; 128(1-2):25-31. PubMed ID: 3019739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PGI2 enhanced cAMP content in bovine coronary arteries in the presence of isobutylmethylxanthine.
    Dembinska-Kiec A; Rücker W; Schönhöfer PS
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Aug; 308(2):107-10. PubMed ID: 91976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PGI2 and PGI analogues on cAMP levels in cultured endothelial and smooth muscle cells derived from bovine arteries.
    Dembinska-Kiec A; Rücker W; Schönhöfer PS
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Feb; 311(1):67-70. PubMed ID: 6154247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostacyclin-induced coronary vasodilation. Interactions with adenosine, cyclic AMP and energy charge in the rat heart in vitro.
    Schrör K; Link HB; Rösen R; Klaus W; Rösen P
    Eur J Pharmacol; 1980 Jun; 64(4):341-8. PubMed ID: 6156077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostacyclin (PGI2) mediates hypoxic relaxation of bovine coronary arterial strips.
    Roberts AM; Messina EJ; Kaley G
    Prostaglandins; 1981 Apr; 21(4):555-69. PubMed ID: 7019974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. dl-9a-Deoxy-9a-methylene-PGI2 (a stable prostacyclin derivative): preliminary pharmacological data.
    Ceserani R; Grossoni M; Longiave D; Mizzotti B; Pozzi O; Dembinska-Kiec A; Bianco S
    Prostaglandins Med; 1980 Aug; 5(2):131-9. PubMed ID: 6251496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological properties of the new stable prostacyclin analogue 3-Oxa-methano-prostaglandin I.
    Yamamoto T; Satoh K; Nishimura T; Horikawa N; Mine T; Hirohashi T; Hara Y
    Arzneimittelforschung; 1994 Apr; 44(4):483-90. PubMed ID: 8011001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The action of the dihydro derivatives of prostacyclin--(6R)-PGI1 and (6S)-PGI1 on the heart and the coronary vasculature.
    Schrör K
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Apr; 306(3):213-7. PubMed ID: 381947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostacyclin (PGI2) is a weak contractor of coronary arteries of the pig.
    Dusting GJ; Moncada S; Vane JR
    Eur J Pharmacol; 1977 Oct; 45(3):301-4. PubMed ID: 336382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological and biochemical parameters of prostacyclin action on the heart and the coronary vasculature.
    Schrör K; Rösen R; Link HB; Rösen P
    Adv Prostaglandin Thromboxane Res; 1980; 7():625-30. PubMed ID: 6154408
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostaglandins and cyclic nucleotides: effects of PGI2 and PGE1 on cardiac hemodynamic and coronary arterial and myocardial cyclic nucleotide levels in dogs.
    Ito T; Ogawa K; Enomoto I; Hashimoto H; Kai I; Sakai K; Satake T
    Jpn Circ J; 1980 Sep; 44(9):755-61. PubMed ID: 6251292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary vasodilation: interactions between prostacyclin and adenosine.
    Blass KE; Förster W; Zehl U
    Br J Pharmacol; 1980 Aug; 69(4):555-9. PubMed ID: 7002243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostacyclin: effects on cyclic AMP in bone cells.
    Robin JC; Brown MJ; Weinfeld N; Dziak R
    Res Commun Chem Pathol Pharmacol; 1982 Jan; 35(1):43-9. PubMed ID: 6276954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic AMP.
    Weithmann KU
    Gen Pharmacol; 1983; 14(1):161-2. PubMed ID: 6298055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relaxation by prostacyclin (PGI2) and 7-oxo-PGI2 of isolated cerebral, coronary and mesenteric arteries.
    Malomvölgyi B; Hadházy P; Magyar K; Kánai K; Simonidesz V
    Acta Physiol Acad Sci Hung; 1982; 60(4):251-6. PubMed ID: 6764858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.